Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum

BACKGROUND: Docetaxel is widely used as a chemotherapeutic agent for gastric cancer treatment. A combined regimen with sunitinib demonstrated a synergistic antitumour effect in a preclinical model. The aim of this study was to evaluate the efficacy and safety of this combination in patients with unr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, J H, Lee, J, Park, S H, Park, J O, Yim, D-S, Park, Y S, Lim, H Y, Kang, W K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341944/
https://www.ncbi.nlm.nih.gov/pubmed/22460270
http://dx.doi.org/10.1038/bjc.2012.100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341944/
https://www.ncbi.nlm.nih.gov/pubmed/22460270
http://dx.doi.org/10.1038/bjc.2012.100

Ejemplares similares